What is Sinusitis Drugs?
Sinusitis drugs or medicines are used for the sinus infection or rhinosinusitis which is caused due to the inflammation of the sinuses creating other issues and symptoms like the plugged nose, pain in the face, thick nasal mucus headache,m fever, sore throat, and other. Drugs range such as analgesics, antibiotics, antihistamines, corticosteroids, decongestants, sulphonamides are consumed for sinus. These sinusitis drugs are prescribed according to the sinus infection which ranges from acute or chronic sinusitis.
The market study is broken down by Type (Analgesics, Antibiotics, Antihistamines, Corticosteroids, Decongestants and Sulphonamides), by Application (Acute Sinusitis and Chronic Sinusitis) and major geographies with country level break-up.
Sanofi S.A. (France), Pfizer Inc. (United States), Novartis International AG (Switzerland), Johnson & Johnson (United States), Merck & Co., Inc. (United States), AstraZeneca plc (United Kingdom), Amgen Inc. (United States) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Sinusitis Drugs market by Type, Application and Region.
On the basis of geography, the market of Sinusitis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Antibiotics will boost the Sinusitis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Adults will boost the Sinusitis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
On 6th August 2020, Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) as add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with INC does not provide adequate disease control1. Phase III studies have shown that Xolair reduces nasal polyp size (defined by Nasal Polyp Score; NPS) and improves symptoms and quality of life in patients with CRSwNP5. Xolair is the first treatment for CRSwNP specifically targeting and blocking immunoglobulin E (IgE), a key driver in the inflammatory pathway of this disease.
"Dupixent is the first FDA approved medicine for adults with chronic rhinosinusitis with nasal polyposis, and the only approved therapy has shown to shrink nasal polyp size and also improve the signs and symptoms of the associated chronic rhinosinusitis."
- Continuous Research and Development in the Sinusitis Drugs
- Increasing Consumption of Analgesics and Antibiotics as Sinusitis Drugs
- Rising Prevalence of Sinus Infection Among Different Range of People
- Need for Treating the Sinus Infection and Other Health Problems Associated with it
- Surging Awareness about the Regular Checkups will Boost the Sinusitis Drugs Market
- Side Effects Associated with the Consumption of Sinusitis Drugs
- Stiff Competition due to New Entrants in the Sinusitis Drugs Market
Key Target Audience
Sinusitis Drugs Manufacturers, Sinusitis Drugs International Traders, Sinusitis Drugs Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others
During this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase